The dependence of prostate cancer on androgen receptor (AR) signalling has been extensively exploited; for example, second-generation AR antagonists such as enzalutamide and apalutamide or the androgen synthesis inhibitor abiraterone have been widely used20,62–65. Here, AR is linked to prostate cancer.